Table of Content

1. Executive Summary
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market

4. Market Overview
    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecasts, 2017-2031

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.3. COVID-19 Pandemic Impact on Industry

6. Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Drug Class
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        6.3.2. Memantine
        6.3.3. Combined Drugs (Memantine & Donepezil)
        6.3.4. Others
    6.4. Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017–2031
        7.3.1. Hospital Pharmacies
        7.3.2. Retail
        7.3.3. Online Sales
    7.4. Market Attractiveness, by Distribution Channel

8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2017–2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region

9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Drug Class, 2017–2031
        9.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        9.2.2. Memantine
        9.2.3. Combined Drugs (Memantine & Donepezil)
        9.2.4. Others
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail
        9.3.3. Online Sales
    9.4. Market Value Forecast, by Country, 2017–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Drug Class
        9.5.2. By Distribution Channel
        9.5.3. By Country

10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017–2031
        10.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        10.2.2. Memantine
        10.2.3. Combined Drugs (Memantine & Donepezil)
        10.2.4. Others
    10.3. Market Value Forecast, by Distribution Channel, 2017–2031
        10.3.1. Hospital Pharmacies
        10.3.2. Retail
        10.3.3. Online Sales
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Drug Class
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region

11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        11.2.2. Memantine
        11.2.3. Combined Drugs (Memantine & Donepezil)
        11.2.4. Others
    11.3. Market Value Forecast, by Distribution Channel, 2017–2031
        11.3.1. Hospital Pharmacies
        11.3.2. Retail
        11.3.3. Online Sales
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Drug Class
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region

12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        12.2.2. Memantine
        12.2.3. Combined Drugs (Memantine & Donepezil)
        12.2.4. Others
    12.3. Market Value Forecast, by Distribution Channel, 2017–2031
        12.3.1. Hospital Pharmacies
        12.3.2. Retail
        12.3.3. Online Sales
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Drug Class
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region
13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
        13.2.2. Memantine
        13.2.3. Combined Drugs (Memantine & Donepezil)
        13.2.4. Others
    13.3. Market Value Forecast, by Distribution Channel, 2017–2031
        13.3.1. Hospital Pharmacies
        13.3.2. Retail
        13.3.3. Online Sales
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Drug Class
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. Merz Pharma
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Novartis AG
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. AbbVie Inc.
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. Pfizer, Inc.
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Daiichi Sankyo Company, Limited.
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Ono Pharmaceutical Co., Ltd.
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. Johnson & Johnson Services, Inc.
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Eisai Co., Ltd.
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. H. Lundbeck A/S
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. F. Hoffmann-La Roche Ltd.
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Product Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview



List of Figures

List of Figures

Figure 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 2: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Drug Class, 2022

Figure 3: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Distribution Channel, 2022

Figure 4: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 5: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 6: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 7: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 8: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Region, 2022 and 2031

Figure 9: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Region, 2023–2031

Figure 10: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country, 2022 and 2031

Figure 12: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country, 2023–2031

Figure 13: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 14: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 15: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 16: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 17: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 18: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 19: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 20: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 21: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 22: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 23: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 24: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 27: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 28: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 29: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 30: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 31: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 34: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 35: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 36: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 37: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 39: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 40: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 41: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 42: Global Dementia Associated with Alzheimer’s Disease Market Share Analysis, by Company (2022)

List of Tables

List of Tables

Table 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 2: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 3: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 4: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 5: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 6: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 7: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 8: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 9: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 10: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 12: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 16: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031